KRON

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
星期四, 五月 23, 2024
Patient, OC, Neutropenia, AACR, KRON, Safety, SAN, NSCLC, Neoplasm, Cancer, MYC, ASCO, Non-Hodgkin lymphoma, Society, Therapy

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the presentation of new data from its ongoing Phase 1/2 study, KB-0742-1001, a first-in-human, open-label dose escalation and cohort expansion study of KB-0742 in patients with relapsed or refractory solid tumors or non-Hodgkin lymphoma, in a poster session at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting being held from May 31 – June 4, 2024 in Chicago, Illinois and online.

Key Points: 
  • In addition, MYC reductions were observed in paired biopsy tumor tissues.
  • This data provides us with confidence that the 80mg four-days-on, three-days-off dose and schedule will show increased patient benefit.
  • Patients enrolled in the study had received a median of three prior treatments (range: 0-9).
  • Patients remained on treatment for an average of >2 cycles and a maximum of 14 completed cycles.

Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events

Retrieved on: 
星期三, 五月 22, 2024
KRON, SAN, Conference, EHA, Cancer, ASCO, Therapy

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that the company would participate in three upcoming healthcare conferences and events.

Key Points: 
  • SAN MATEO, Calif. and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that the company would participate in three upcoming healthcare conferences and events.
  • Norbert Bischofberger, Ph.D., president and chief executive officer, will represent the company at these events.
  • May 28th, 2024, Dr. Bischofberger will participate in a virtual fireside chat at 2:00 p.m. ET/11:00 a.m. PT at the TD Cowen's 5th Annual Oncology Innovation Summit: Insights for ASCO and EHA.
  • A live audio webcast of the events will be available on the Investors and Media section of the Kronos Bio website at https://ir.kronosbio.com/events-presentations .

Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer 

Retrieved on: 
星期二, 五月 21, 2024
Synthetic biology, JPMorgan Chase, AB, Pfizer, University, KRON, SAN, Research, Duke University, Cancer, Accounting, J.P. Morgan & Co., Therapy, Biotechnology, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it has appointed Deborah Knobelman, Ph.D., as Chief Operating Officer and Chief Financial Officer effective June 3, 2024.

Key Points: 
  • SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it has appointed Deborah Knobelman, Ph.D., as Chief Operating Officer and Chief Financial Officer effective June 3, 2024.
  • She is a proven life sciences leader, and her strategic vision will play a critical role in shaping the future of Kronos Bio.
  • Dr. Knobelman was previously chief financial officer and head of corporate development for Senti Bio, a biotechnology company that utilized a synthetic biology platform to enable programming of next-generation cell therapies.
  • Prior to Senti, Dr. Knobelman served in interim C-suite roles for several life sciences companies, including Jogo Health, Thinklabs, and Aktiv Pharma Group, and served as chief financial officer at GeneriCo, LLC and chief business officer at Ampio Pharmaceuticals, Inc.

Kronos Bio Reports First-Quarter 2024 Financial Results

Retrieved on: 
星期四, 五月 9, 2024
CDK9, Investment, Research, KRON, Genentech, IND, ASCO, Therapy, Patient, Society, AACR, Adenoid cystic carcinoma, Cancer, SAN, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today reported recent business progress and financial results for the first-quarter of 2024.

Key Points: 
  • SAN MATEO, Calif. and CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today reported recent business progress and financial results for the first-quarter of 2024.
  • R&D Expenses: Research and development expenses were $14.2 million for the first quarter of 2024, which includes non-cash stock-based compensation expense of $1.2 million.
  • Impairment of Long-lived Assets and Restructuring: The Company incurred impairment of long-lived assets expense of $6.6 million for the first quarter of 2024.
  • The Company also incurred restructuring expense of $6.2 million for the first quarter of 2024, which includes non-cash stock-based compensation of $4.4 million.

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
星期三, 四月 24, 2024
Cancer, CDK9, Safety, KRON, ASCO, Society, AACR, Annual general meeting, SAN, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present a study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors from the ongoing Phase 1/2 trial, KB-0742-1001 ( NCT04718675 ), at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held from May 31 – June 4, 2024 in Chicago, Illinois and online.

Key Points: 
  • SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present a study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors from the ongoing Phase 1/2 trial, KB-0742-1001 ( NCT04718675 ), at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held from May 31 – June 4, 2024 in Chicago, Illinois and online.
  • “We are looking forward to sharing updated data from KB-0742-1001, our ongoing Phase 1/2 trial of KB-0742, including data from the 80mg three days on/four days off dosing regimen.
  • The trial is designed to assess the safety, tolerability, and preliminary efficacy at increasing dose levels of KB-0742, an orally bioavailable and selective CDK9 inhibitor with a long half-life,” said Norbert Bischofberger, Ph.D., chief executive officer and president of Kronos Bio.
  • “Our last update at the 2023 AACR-NCI-EORTC meeting showed that KB-0742 exhibited anti-tumor activity while maintaining an acceptable safety profile at the 60mg three-days-on, four-days-off dose, which is an important step as we seek to identify the optimal dose of KB-0742.”
    Details for the ASCO 2024 abstract are as follows:

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results

Retrieved on: 
星期四, 三月 21, 2024
Research, Ovarian cancer, Conference, Survival, AML, Carcinoma, RECIST, Patient, SAN, Multiple myeloma, KRON, Cancer, IRF4, Lung cancer, IND, AACR, Investment, KAT, CDK9, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and fourth-quarter and full-year 2023 financial results.

Key Points: 
  • “In 2023, we made great progress across our portfolio and business.
  • Kronos Bio extended its expected cash runway by a year, into the second half of 2026, through restructurings and resource optimization.
  • Net Loss: Net loss for the fourth quarter of 2023 was $25.3 million, or $0.43 per share, including non-cash stock-based compensation expense of $5.2 million.
  • Net loss for the full-year 2023 was $112.7 million, or $1.95 per share, including non-cash stock-based compensation expense of $25.0 million.

Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway

Retrieved on: 
星期四, 三月 7, 2024
SAN, KRON, AACR, Lung cancer, Safety, Genentech, Ovarian cancer, Patient, Multiple myeloma, CDK9, IND, KAT, Cancer, Pharmaceutical industry

SAN MATEO, Calif., and CAMBRIDGE, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced a plan to optimize its resource allocation, restructure, and extend runway to focus resources on key programs in the Company’s pipeline, including the ongoing phase 1/2 study of KB-0742 following the review of additional positive preliminary safety and efficacy data. This plan positions the Company to maximize the potential of KB-0742, an inhibitor of CDK9, by exploring an extended dosing schedule while also continuing to progress KB-9558, a p300 KAT inhibitor, through ongoing IND-enabling studies and into the clinic, and its discovery efforts and collaborations. The Company expects these efforts, which include a 21% reduction in force, will extend cash runway into the second half of 2026.

Key Points: 
  • The Company expects these efforts, which include a 21% reduction in force, will extend cash runway into the second half of 2026.
  • The Company has reported target engagement, tumor regressions, and an acceptable safety profile at 60mg dosed three-days-on, four-days-off.
  • KB-0742 cleared 80mg three-days-on, four-days-off and the Company expects to publish this data in addition to the 60mg expansion mid-year.
  • Pending the completion of IND-enabling studies in 2024, the Company expects to commence a first-in-human study in multiple myeloma in 2025.

Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting

Retrieved on: 
星期二, 三月 5, 2024
SAN, IRF4, Senior, KRON, Research, Research and development, Adenoid cystic carcinoma, AACR, Molecular biology, Gene expression, Abstract, Multiple myeloma, CDK9, KAT, Development, Cancer, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California.

Key Points: 
  • SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California.
  • “We are excited to present our data at AACR showing that targeting p300’s enzymatic KAT domain can selectively downregulate IRF4, a long sought after transcription factor dependency in multiple myeloma.
  • Although p300 is an essential gene, our data show that through its relationship as a critical IRF4 cofactor, we can achieve selective antiproliferative effects against myeloma cells,” said Charles Lin, Ph.D., Senior Vice President, Research and Development of Kronos Bio.
  • Details for the AACR 2024 abstracts are as follows:
    Title: A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in relapsed, refractory and transcriptionally addicted solid tumors
    Title: KB-0742, an oral highly selective CDK9 inhibitor, demonstrates preclinical activity in transcription factor fusion driven adenoid cystic carcinoma patient-derived models
    Poster Session: Molecular Biology in Clinical Oncology: Characterizing and Modulating Epigenetics and Gene Expression

Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference

Retrieved on: 
星期二, 二月 27, 2024
SAN, KRON, Webcast, Cancer, Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the 44th Annual Cowen Health Care Conference, taking place March 4-6, 2024, in Boston, Massachusetts.

Key Points: 
  • SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the 44th Annual Cowen Health Care Conference, taking place March 4-6, 2024, in Boston, Massachusetts.
  • Kronos Bio President and Chief Executive Officer Norbert Bischofberger, Ph.D., will participate in the “Novel Oncology Targets” panel discussion on Tuesday, March 5, at 9:10 a.m.
  • A live audio webcast of the event will be available on the Investors and Media section of the Kronos Bio website at www.kronosbio.com .
  • A replay of the webcast will be available for 30 days following the event.

Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement

Retrieved on: 
星期四, 一月 25, 2024
SAN, KRON, IND, General counsel, Security (finance), Cancer, Therapy, Management

SAN MATEO, Calif., and CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced a streamlined leadership structure designed to focus on pipeline advancement and align with Kronos Bio’s current operating needs.

Key Points: 
  • SAN MATEO, Calif., and CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced a streamlined leadership structure designed to focus on pipeline advancement and align with Kronos Bio’s current operating needs.
  • “This new leadership structure is designed to streamline our operations and reflects our ongoing effort to advance our pipeline, optimize our resources, and efficiently deliver on our business objectives,” said Norbert Bischofberger, Ph.D., President and Chief Executive Officer of Kronos Bio.
  • To learn more about the Kronos Bio leadership team, please visit: https://www.kronosbio.com/company/#leadership
    “I am confident that Kronos Bio has the right leadership to progress the KB-0742 clinical program, advance KB-9558 through IND-enabling studies and beyond, and to continue to deliver on its collaborations,” said Dr. DiMartino.
  • After realizing these one-time termination costs, Kronos Bio anticipates that it will realize financial savings from its new operating model.